Skip to main content

Table 3 Principle outcomes of the constant effect analyses*

From: Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

 

Comparator

Treatment

No drug treatment

Rivastigmine

Donepezil

Galantamine

  

1–4 mg

6–12 mg

5 mg

10 mg

16 mg

Rivastigmine

      

1–4 mg

3.0%** $2,880 $224,222

     

6–12 mg

5.8% $514 $36,161

3.0% -$2,370 Dominant

    

Donepezil

      

5 mg

6.6% $1,032 $36,161

3.7% -$1,849 Dominant

0.8% $522 $158,875

   

10 mg

9.5% -$811 Dominant

6.7% -$3,692 Dominant

3.9% -$1,321 Dominant

3.1% -$1,843 Dominant

  

Galantamine

      

16 mg

10.2% -$1,134 Dominant

7.5% -$4,015 Dominant

4.6% -$1,644 Dominant

3.9% -$2,166 Dominant

0.8% -$323 Dominant

 

24 mg

10.3% -$1,366 Dominant

7.6% -$4,246 Dominant

4.7% -$1,876 Dominant

4.0% -$2,398 Dominant

0.9% -$555 Dominant

0.1% -$232 Dominant

  1. * for each drug treatment in the rows the comparison is made relative to the approach in the column ** percent reduction in time spent requiring FTC net costs incremental cost per QALY gained